These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Therapeutic Effect of Cyclin-Dependent Kinase 4/6 Inhibitor on Dermal Fibrosis in Murine Models of Systemic Sclerosis. Yamamoto A; Saito T; Hosoya T; Kawahata K; Asano Y; Sato S; Mizoguchi F; Yasuda S; Kohsaka H Arthritis Rheumatol; 2022 May; 74(5):860-870. PubMed ID: 34882985 [TBL] [Abstract][Full Text] [Related]
24. A profibrotic role for thymic stromal lymphopoietin in systemic sclerosis. Usategui A; Criado G; Izquierdo E; Del Rey MJ; Carreira PE; Ortiz P; Leonard WJ; Pablos JL Ann Rheum Dis; 2013 Dec; 72(12):2018-23. PubMed ID: 23413283 [TBL] [Abstract][Full Text] [Related]
25. Tanshinone IIA ameliorates the development of dermal fibrosis in systemic sclerosis. Jiang Y; Hu F; Li M; Li Q Clin Exp Pharmacol Physiol; 2024 Feb; 51(2):e13834. PubMed ID: 38037494 [TBL] [Abstract][Full Text] [Related]
26. Single-cell sequencing reveals the antifibrotic effects of YAP/TAZ in systemic sclerosis. Wu D; Wang W; Li X; Yin B; Ma Y Int J Biochem Cell Biol; 2022 Aug; 149():106257. PubMed ID: 35772663 [TBL] [Abstract][Full Text] [Related]
27. Sirt1 regulates canonical TGF-β signalling to control fibroblast activation and tissue fibrosis. Zerr P; Palumbo-Zerr K; Huang J; Tomcik M; Sumova B; Distler O; Schett G; Distler JH Ann Rheum Dis; 2016 Jan; 75(1):226-33. PubMed ID: 25180292 [TBL] [Abstract][Full Text] [Related]
29. CXCL17-mediated downregulation of type I collagen via MMP1 and miR-29 in skin fibroblasts possibly contributes to the fibrosis in systemic sclerosis. Shimada S; Makino K; Jinnin M; Sawamura S; Kawano Y; Ide M; Kajihara I; Makino T; Fukushima S; Ihn H J Dermatol Sci; 2020 Dec; 100(3):183-191. PubMed ID: 33055012 [TBL] [Abstract][Full Text] [Related]
30. Sirt1 ameliorates systemic sclerosis by targeting the mTOR pathway. Zhu X; Chu H; Jiang S; Liu Q; Liu L; Xue Y; Zheng S; Wan W; Qiu J; Wang J; Zou H J Dermatol Sci; 2017 Aug; 87(2):149-158. PubMed ID: 28532580 [TBL] [Abstract][Full Text] [Related]
31. Angiotensin II in the lesional skin of systemic sclerosis patients contributes to tissue fibrosis via angiotensin II type 1 receptors. Kawaguchi Y; Takagi K; Hara M; Fukasawa C; Sugiura T; Nishimagi E; Harigai M; Kamatani N Arthritis Rheum; 2004 Jan; 50(1):216-26. PubMed ID: 14730619 [TBL] [Abstract][Full Text] [Related]
32. Antifibrotic effects and mechanisms of mesenchymal stem cell-derived exosomes in a systemic sclerosis mouse model: Possible contribution of miR-196b-5p. Baral H; Uchiyama A; Yokoyama Y; Sekiguchi A; Yamazaki S; Amalia SN; Inoue Y; Ogino S; Torii R; Hosoi M; Matsuzaki T; Motegi SI J Dermatol Sci; 2021 Oct; 104(1):39-47. PubMed ID: 34479773 [TBL] [Abstract][Full Text] [Related]
34. The Antifibrotic Effect of α2AP Neutralization in Systemic Sclerosis Dermal Fibroblasts and Mouse Models of Systemic Sclerosis. Kanno Y; Shu E; Kanoh H; Seishima M J Invest Dermatol; 2016 Apr; 136(4):762-769. PubMed ID: 26743600 [TBL] [Abstract][Full Text] [Related]
35. Involvement of Disabled-2 on skin fibrosis in systemic sclerosis. Mei X; Zhao H; Huang Y; Tang Y; Shi X; Pu W; Jiang S; Ma Y; Zhang Y; Bai L; Tu W; Zhao Y; Jin L; Wu W; Wang J; Liu Q J Dermatol Sci; 2020 Jul; 99(1):44-52. PubMed ID: 32571632 [TBL] [Abstract][Full Text] [Related]
36. The fibrotic phenotype of systemic sclerosis fibroblasts varies with disease duration and severity of skin involvement: reconstitution of skin fibrosis development using a tissue engineering approach. Corriveau MP; Boufaied I; Lessard J; Chabaud S; Senécal JL; Grodzicky T; Chartier S; Raymond Y; Moulin VJ J Pathol; 2009 Mar; 217(4):534-42. PubMed ID: 19086038 [TBL] [Abstract][Full Text] [Related]
37. Jun N-terminal kinase as a potential molecular target for prevention and treatment of dermal fibrosis. Reich N; Tomcik M; Zerr P; Lang V; Dees C; Avouac J; Palumbo K; Horn A; Akhmetshina A; Beyer C; Xie W; Bennett BL; Distler O; Schett G; Distler JH Ann Rheum Dis; 2012 May; 71(5):737-45. PubMed ID: 22258492 [TBL] [Abstract][Full Text] [Related]
38. Suppressive Regulation by MFG-E8 of Latent Transforming Growth Factor β-Induced Fibrosis via Binding to αv Integrin: Significance in the Pathogenesis of Fibrosis in Systemic Sclerosis. Fujiwara C; Uehara A; Sekiguchi A; Uchiyama A; Yamazaki S; Ogino S; Yokoyama Y; Torii R; Hosoi M; Suto C; Tsunekawa K; Murakami M; Ishikawa O; Motegi SI Arthritis Rheumatol; 2019 Feb; 71(2):302-314. PubMed ID: 30175895 [TBL] [Abstract][Full Text] [Related]
39. Identification of cadherin 11 as a mediator of dermal fibrosis and possible role in systemic sclerosis. Wu M; Pedroza M; Lafyatis R; George AT; Mayes MD; Assassi S; Tan FK; Brenner MB; Agarwal SK Arthritis Rheumatol; 2014 Apr; 66(4):1010-21. PubMed ID: 24757152 [TBL] [Abstract][Full Text] [Related]
40. Antifibrotic effect of apremilast in systemic sclerosis dermal fibroblasts and bleomycin-induced mouse model. Higuchi T; Takagi K; Tochimoto A; Ichimura Y; Hirose H; Sawada T; Shibata N; Harigai M; Kawaguchi Y Sci Rep; 2023 Nov; 13(1):19378. PubMed ID: 37938601 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]